Pseudomonas aeruginosa phenotypes associated with eradication failure in childrenwith cystic fibrosis

Clinical Infectious Diseases

Volumn 59, Issue 5, 2014, Pages 624-631

  Mayer Hamblett, Nicole ^a,b,c   Ramsey, Bonnie W ^a,c   Kulasekara, Hemantha D ^b   Wolter, Daniel J ^a   Houston, Laura S ^a   Pope, Christopher E ^a   Kulasekara, Bridget R ^b   Armbruster, Catherine R ^b   Burns, Jane L ^a,c   Retsch Bogart, George ^d   Rosenfeld, Margaret ^a,c   Gibson, Ronald L ^a,c   Miller, Samuel I ^b   Khan, Umer ^c   Hoffman, Lucas R ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic treatment; Cystic fibrosis; Eradication; Phenotypic characterization; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; GLYCOSAMINOGLYCAN; MUCOID EXOPOLYSACCHARIDE (P AERUGINOSA);

ARTICLE; BACTERIUM COLONY; BACTERIUM DETECTION; BACTERIUM ISOLATE; BIOFILM; CHILD; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE MARKER; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; TREATMENT OUTCOME; COMPLICATION; CYSTIC FIBROSIS; CYTOLOGY; DRUG EFFECTS; GENETICS; GENOTYPE; INFANT; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTIONS; TREATMENT FAILURE;

BIOFILMS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; GENOTYPE; GLYCOSAMINOGLYCANS; HUMANS; INFANT; MALE; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT FAILURE;

EID: 84907415315     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu385     Document Type: Article

References (40)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918-51. (Pubitemid 37267172)
2. Cystic Fibrosis Foundation. Patient registry report 2012. Available at: http://www.cff.org/UploadedFiles/research/ClinicalResearch/ PatientRegistryReport/2012-CFF-Patient-Registry.pdf. Accessed 2 June 2014.
3. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338:725-6.
4. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25:88-92. (Pubitemid 28110583)
5. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167:841-9. (Pubitemid 36801771)
6. Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2013; 12:29-34.
7. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. In: The Cochrane Collaboration, Langton Hewer SC, ed, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2009. Available at: http://doi.wiley.com/10.1002/14651858.CD004197.pub3. Accessed 21 November 2013.
8. Ratjen F, Munck A, Kho P, Angyalosi G, ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65:286-91.
9. Döring G, Parameswaran IG, Murphy TF. Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol Rev 2011; 35:124-46.
10. D'Argenio DA, Wu M, Hoffman LR, et al. Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol 2007; 64:512-33. (Pubitemid 46632635)
11. Folkesson A, Jelsbak L, Yang L, et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol 2012; 10:841-51.
12. Hogardt M, Heesemann J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int J Med Microbiol 2010; 300:557-62.
13. Manos J, Hu H, Rose BR, et al. Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2013; 32:1583-92.
14. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293:581-8. (Pubitemid 40171240)
15. Doggett RG. Incidence of mucoid Pseudomonas aeruginosa from clinical sources. Appl Microbiol 1969; 18:936-7.
16. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991; 4:35-51. (Pubitemid 21920386)
17. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34:91-100. (Pubitemid 34809519)
18. Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 2006; 103:8487-92. (Pubitemid 43838482)
19. Hoffman LR, Kulasekara HD, Emerson J, et al. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros 2009; 8:66-70.
20. Ren CL, Konstan MW, Yegin A, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros 2012; 11:293-9.
21. Hunter RC, Klepac-Ceraj V, Lorenzi MM, Grotzinger H, Martin TR, Newman DK. Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. Am J Respir Cell Mol Biol 2012; 47:738-45.
22. Tramper-Stranders GA, van der Ent CK, Molin S, et al. Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. Clin Microbiol Infect 2012; 18:567-74.
23. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007; 42:610-23. (Pubitemid 47022973)
24. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165:847-56.
25. Mayer-Hamblett N, Kronmal RA, Gibson RL, et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012; 47:125-34.
26. Hoffman LR, Richardson AR, Houston LS, et al. Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway. PLoS Pathog 2010; 6:e1000712.
27. Gupta R, Schuster M. Quorum sensing modulates colony morphology through alkyl quinolones in Pseudomonas aeruginosa. BMC Microbiol 2012; 12:30.
28. D'Argenio DA, Calfee MW, Rainey PB, Pesci EC. Autolysis and autoaggregation in Pseudomonas aeruginosa colony morphology mutants. J Bacteriol 2002; 184:6481-9. (Pubitemid 35332551)
29. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001; 183:444-52. (Pubitemid 32105604)
30. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 2002; 34:232-6. (Pubitemid 34971079)
31. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011; 24:29-70.
32. Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 1994; 62:596-605. (Pubitemid 24033780)
33. Cramer N, Wiehlmann L, Tümmler B. Clonal epidemiology of Pseudomonas aeruginosa in cystic fibrosis. Int J Med Microbiol 2010; 300:526-33.
34. Hansen SK, Rau MH, Johansen HK, et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 2012; 6:31-45.
35. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999; 28:321-8. (Pubitemid 29523443)
36. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123:1495-502. (Pubitemid 36549768)
37. Foweraker JE, Laughton CR, Brown DFJ, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 55:921-7. (Pubitemid 40883177)
38. Wilder CN, Allada G, Schuster M. Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections. Infect Immun 2009; 77:5631-9.
39. Workentine ML, Sibley CD, Glezerson B, et al. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS One 2013; 8:e60225.
40. Ashish A, Paterson S, Mowat E, Fothergill JL, Walshaw MJ, Winstanley C. Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis. J Cyst Fibros 2013; 12:790-3.